Abstract:Aim: Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk and competition, are multi-dimensional issues in medical economics that remain under-explored in the current empirical literature. We seek to address these issues in reviewing relevant studies presented at the 2020 AEA-ASSA annual convention. Approach: Drawn from the 2020 convention panel sessions devoted to health economics, empirical evidence was thematically analyzed for charted new research terrains and trajectories. Their theoretical and practical implications on efficiency, effectiveness, and value in drug production and consumption were then identified. Findings: With certain qualifications, evidence confirms price inelasticity of prescription drugs and medical treatments, along with substitution effects from high or continuously rising prices. While health insurance induces ex ante moral hazard, albeit on a larger scale than previously considered, losing dependent coverage can incentivize price-substitution to risky and illegal drugs, including those sold on the black market. At the firm level, drug patenting and exclusivity rights suggest that innovation incentives increase new or novel clinical trials and generic utilization to a considerable extent. But innovation can produce strong, offsetting effects. It can distort competition and cause (at times sharp) price increases from product-hopping, (compensatory) list pricing, industry mergers and acquisitions, and capture of positive spillovers by competitors, rather than by focal developers, in follow-on innovations. In fine, there remains room for opportunism among firms, particularly market incumbents, and many loopholes are unplugged by U.S. healthcare reform. These make drug utilization costly to the insured, and risky to those who are - or become - uninsured or underinsured for various reasons. Conclusions: The fundamental disconnect between innovation cost and drug pricing demands public attention and policy intervention, which have proved largely elusive to date. Gaming the system in the name of scientific invention and discovery to reap additional benefits, at the expense of consumer health and income, brings to question the offsetting benefits of firm innovation. It also raises separate issues of fairness and equity. Innovation needs to be considered from the perspective of value lines and beyond conventional marketing incentives to drug utilization, with or without insurance coverage. Cost-effectiveness and cost-benefit analyses figure prominently under a value-based system of resource allocation, insurance, medical prescription, purchasing, and reimbursement.

Projected prescription drug expenditures in 2024: Looking ahead to the inflation reduction era

National trends in prescription drug expenditures and projections for 2024

Recent and anticipated novel drug approvals for 2024

Managing the unexpected: considerations for new pharmacy leaders

Drug shortage stewardship: A novel solution for an old problem

ASHP and ASHP Foundation Pharmacy Forecast 2024: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

ASHP Foundation Pharmacy Forecast 2021: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems

Escalating costs of innovative medicines: perspective and proposals

Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act

National Health Expenditure Projections, 2016-25: Price Increases, Aging Push Sector To 20 Percent Of Economy

Guidance on using Medicaid web portals and other electronic prescriptions claims data to improve admission medication reconciliation in critical access hospitals

Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025

Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics

Auditing the prescription drug consumer price index in a changing marketplace

Maximizing opioid stewardship through fentanyl vial size optimization in an independent hospital

Practice-enhancing publications about the medication-use process in 2023

Resources and strategies for learning infectious diseases pharmacotherapy during advanced pharmacy practice experiences and pharmacy residency

The Inflation Reduction Act and Patient Costs for Drugs to Treat Heart Failure

Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug Program

Mission control: Incorporating operations centers in hospital pharmacy design